Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 3/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.39 |
| ▸ | CTRB1 | P17538 | 5/20 | 0.38 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.36 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.35 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.35 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.35 |
| ▸ | MMP1 | P03956 | 6/20 | 0.35 |
| ▸ | MMP3 | P08254 | 6/20 | 0.35 |
| ▸ | MMP9 | P14780 | 6/20 | 0.35 |
| ▸ | MMP2 | P08253 | 5/20 | 0.35 |
| ▸ | MMP8 | P22894 | 4/20 | 0.35 |
| ▸ | MMP13 | P45452 | 3/20 | 0.35 |
| ▸ | FAP | Q12884 | 1/20 | 0.34 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.34 |
| ▸ | MMP7 | P09237 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30853669 | 0.83 | DPP4 (0.52) | DPP4CA2SLC7A5ALDH1A1MAPT | |
| SCHEMBL7049300 | 0.80 | SLC7A5 (0.52) | SLC7A5MMP1MMP3MMP9MMP2 | |
| SCHEMBL27501940 | 0.80 | SLC7A5 (0.52) | SLC7A5MMP1MMP3MMP9MMP2 | |
| SCHEMBL27502709 | 0.77 | PTGS1 (0.47) | CA2ALDH1A1MAPTPTGS1MMP1 | |
| SCHEMBL27924591 | 0.76 | CA2 (0.45) | DPP4CA2SLC7A5ALDH1A1MAPT | |
| SCHEMBL10453345 | 0.76 | DPP4 (0.50) | DPP4SLC7A5CTRB1DPP8DPP7 | |
| SCHEMBL9608873 | 0.76 | DPP4 (0.50) | DPP4CTRB1DPP8DPP7ALDH1A1 | |
| SCHEMBL3790653 | 0.76 | CA2 (0.45) | DPP4CA2SLC7A5ALDH1A1MAPT | |
| SCHEMBL7526611 | 0.76 | CA2 (0.45) | DPP4CA2SLC7A5ALDH1A1MAPT | |
| SCHEMBL8357912 | 0.75 | CA2 (0.43) | CA2SLC7A5ALDH1A1MAPTPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260124212-A1 | MAYTANSINOID DERIVATIVES WITH SELF-IMMOLATIVE PEPTIDE LINKERS AND CONJUGATES THEREOF | IMMUNOGEN INC (US) | 2026-05-07 | — | — | US | claimed |
| US-12390471-B2 | Maytansinoid derivatives with self-immolative peptide linkers and conjugates thereof | IMMUNOGEN, INC. (US) | 2025-08-19 | — | — | US | claimed |
| US-20240226312-A1 | TREATMENT OF CANCER IN PATIENTS WITH SOLUBLE FR-ALPHA | IMMUNOGEN, INC. (US) | 2024-07-11 | — | — | US | claimed |
| US-20240165256-A1 | METHODS FOR INCREASING EFFICACY OF IMMUNOCONJUGATES TARGETING ADAM9 FOR THE TREATMENT OF CANCER | IMMUNOGEN INC (US) | 2024-05-23 | — | — | US | claimed |
| CN-117729942-A | Methods for increasing efficacy of ADAM 9-targeted immunoconjugates in the treatment of cancer | 伊缪诺金公司 | 2024-03-19 | — | — | CN | claimed |
| CN-117730098-A | Treatment of cancer in patients with soluble FR-alpha | 伊缪诺金公司 | 2024-03-19 | — | — | CN | claimed |
| CN-116785450-A | Maytansinoid derivatives with self-cleaving peptide linker and conjugates thereof | 伊缪诺金公司 | 2023-09-22 | — | — | CN | claimed |
| CN-116785451-A | Maytansinoid derivatives with self-cleaving peptide linker and conjugates thereof | 伊缪诺金公司 | 2023-09-22 | — | — | CN | claimed |
| CN-110366431-B | Maytansinoid derivatives with self-cleaving peptide linker and conjugates thereof | 伊缪诺金公司 | 2023-07-18 | — | — | CN | claimed |
| US-20220111067-A1 | MAYTANSINOID DERIVATIVES WITH SELF-IMMOLATIVE PEPTIDE LINKERS AND CONJUGATES THEREOF | IMMUNOGEN SWITZERLAND GMBH (CH) | 2022-04-14 | — | — | US | claimed |
| CN-114222756-A | Biparatopic FR-alpha antibodies and immunoconjugates | 伊缪诺金公司 | 2022-03-22 | — | — | CN | claimed |
| EP-3962935-A1 | BIPARATOPIC FR-ALPHA ANTIBODIES AND IMMUNOCONJUGATES | Immunogen, Inc. (US) | 2022-03-09 | — | — | EP | claimed |
| EP-3941527-A1 | METHODS OF PREPARING CELL-BINDING AGENT-DRUG CONJUGATES | ImmunoGen, Inc. (US) | 2022-01-26 | — | — | EP | claimed |
| US-20260124212-A1 | MAYTANSINOID DERIVATIVES WITH SELF-IMMOLATIVE PEPTIDE LINKERS AND CONJUGATES THEREOF | IMMUNOGEN INC (US) | 2026-05-07 | — | — | US | disclosed |
| EP-4736955-A2 | EPCAM ANTIBODIES, ACTIVATABLE ANTIBODIES, AND IMMUNOCONJUGATES, AND USES THEREOF | ImmunoGen, Inc. (US) | 2026-05-06 | — | — | EP | disclosed |
| US-20260061058-A1 | BIPARATOPIC FR-ALPHA ANTIBODIES AND IMMUNOCONJUGATES | IMMUNOGEN INC (US) | 2026-03-05 | — | — | US | disclosed |
| US-20220111067-A1 | MAYTANSINOID DERIVATIVES WITH SELF-IMMOLATIVE PEPTIDE LINKERS AND CONJUGATES THEREOF | IMMUNOGEN SWITZERLAND GMBH (CH) | 2022-04-14 | — | — | US | disclosed |
| CN-114222756-A | Biparatopic FR-alpha antibodies and immunoconjugates | 伊缪诺金公司 | 2022-03-22 | — | — | CN | disclosed |
| EP-3962935-A1 | BIPARATOPIC FR-ALPHA ANTIBODIES AND IMMUNOCONJUGATES | Immunogen, Inc. (US) | 2022-03-09 | — | — | EP | disclosed |
| EP-3941527-A1 | METHODS OF PREPARING CELL-BINDING AGENT-DRUG CONJUGATES | ImmunoGen, Inc. (US) | 2022-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12390471-B2 | Maytansinoid derivatives with self-immolative peptide linkers and conjugates thereof | VIP, AREG, MIF | DPP4 1262/4885CA2 2709/4885SLC7A5 821/4885 |
| US-20240165256-A1 | METHODS FOR INCREASING EFFICACY OF IMMUNOCONJUGATES TARGETING ADAM9 FOR THE TREATMENT OF CANCER | ADAM9, TMPRSS15, ADAM17 | DPP4 466/4885CA2 1841/4885SLC7A5 2205/4885 |
| US-20220111067-A1 | MAYTANSINOID DERIVATIVES WITH SELF-IMMOLATIVE PEPTIDE LINKERS AND CONJUGATES THEREOF | VIP, AREG, MIF | DPP4 1262/4885CA2 2709/4885SLC7A5 821/4885 |
| US-20240226312-A1 | TREATMENT OF CANCER IN PATIENTS WITH SOLUBLE FR-ALPHA | FOLR1, FOLR2, FRS2 | DPP4 4488/4885CA2 4762/4885SLC7A5 2583/4885 |
| US-20260124212-A1 | MAYTANSINOID DERIVATIVES WITH SELF-IMMOLATIVE PEPTIDE LINKERS AND CONJUGATES THEREOF | VEGFA, VIP, AREG | DPP4 2235/4885CA2 1821/4885SLC7A5 53/4885 |
| US-20260061058-A1 | BIPARATOPIC FR-ALPHA ANTIBODIES AND IMMUNOCONJUGATES | IGSF11, FOLR2, FOLR1 | DPP4 4850/4885CA2 2559/4885SLC7A5 1687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.